Research Purposes Only: The compounds discussed on this site (BPC-157, TB-500) are explicitly for laboratory research use only. They are not FDA-approved for human consumption, medical treatment, or dietary supplementation. The information provided is for educational and harm-reduction purposes and does not constitute medical advice.

Data Collection

Our Methodology

Last Updated: March 2026

Wolverine Stack takes a data-driven approach to mapping the regenerative peptide landscape. Our methodology outlines how we discover, evaluate, and classify research data regarding BPC-157, TB-500, and their synergistic applications.

Data Sourcing

We source information exclusively from recognized scientific databases:

  • PubMed and MEDLINE
  • The National Institutes of Health (NIH)
  • The Directory of Open Access Journals (DOAJ)
  • ClinicalTrials.gov

We actively ignore commercially sponsored "white papers" from peptide synthesis companies, treating them as marketing material rather than clinical evidence.

Evidence Grading System

A primary issue in the peptide space is conflating *in vitro* (petri dish) results with human efficacy. We use a strict tagging system across the site, denoted by our Evidence Badges:

Human RCT

Randomized, double-blind, placebo-controlled human trials. The gold standard of evidence.

Animal Pattern

In vivo studies conducted on rats, mice, dogs, or horses. Indicates biological plausibility but not guaranteed human crossover.

In Vitro

Cell cultures outside a living organism. Useful for mechanism identification, completely unproven for clinical outcomes.

Anecdotal / Survey

Aggregated user reports or physician case studies. Unverified, highly subject to placebo, but useful for identifying trends.

Content Updates

Our database of studies is reviewed quarterly. As new trials are published (or as FDA/WADA regulatory statuses shift), our methodology dictates a prompt refactoring of relevant core pages to reflect the current scientific consensus.